Close

Shkreli Rubs Salt in KaloBios Pharma (KBIO) Short Sellers' Wounds

November 23, 2015 12:55 PM EST

KaloBios Pharma (NASDAQ: KBIO) new CEO Martin Shkreli just tweeted a picture of himself and others at the company's headquarters captioned "turnaround in progress."

Shares have surged from $0.90 to over $45 in a few days amid news a Shkreli group has accumulated nearly the entire float and will takeover as CEO, staving off a wind-down. An epic short squeeze has ensued.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Management Comments, Momentum Movers, Short Sales, Trader Talk